Last reviewed · How we verify
NCT04380584
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
trial testing plasma Apelin level in Diabetic Nephropathies in 90 participants. Completed in 29 March 2020.
20 March 2020
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 30 November 2019 |
| Primary completion | 20 March 2020 |
| Estimated completion | 29 March 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- plasma Apelin level
Conditions studied
- Diabetic Nephropathies — all drugs for Diabetic Nephropathies →
Sponsor
Cairo University
Who can join
Adults 20 to 60, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease, and proteinuria isn't determent factor for the end stage renal disease in diabetics. Apelin is adipokine and have a beneficial role in early prediction of diabetic nephropathy. Few studies were done about apelin in diabetes. Purpose of the study: to investigate the association between the apelinergic system and diabetic nephropathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Connection between the Plasma Level of Apelin and Diabetic Nephropathy in Type 2 Diabetic Patients. A Case Control Study.
Helmy MY, Hamdy N, Ghaffar NAE. · · 2021 · cited 2× · PMID 35300444 · DOI 10.4103/ijem.ijem_300_21
Verify or expand the search:
- PubMed search for NCT04380584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Nephropathies
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07187713 — ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases · Phase 4 · recruiting
- NCT06778018 — Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy · NA · recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06431477 — Efficacy and Safety of Telmisartan Compared With Losartan · Phase 4 · recruiting
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04380584 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 11 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04380584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing